导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 1.73% | 1830/4773 |
| 近一周 | -3.14% | 3755/5462 |
| 近一月 | -9.90% | 4919/5421 |
| 近一季 | -18.50% | 4712/5209 |
| 近半年 | -1.34% | 1561/4920 |
| 近一年 | 6.11% | 1504/4366 |
| 近两年 | 105.36% | 548/2954 |
| 近三年 | 61.29% | 428/2253 |
| 成立以来 | 30.87% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-0.68% 1908/4961 |
34.72% 950/5312 |
- - |
- - |
| 2025 | 48.10% 541/4813 |
-1.81% 2783/3635 |
3.20% 1117/4076 |
47.60% 445/4524 |
-0.98% 2763/4813 |
| 2024 | 12.85% 1205/3463 |
-3.65% 1535/2808 |
-6.26% 1896/3014 |
27.35% 231/3129 |
-1.89% 1876/3463 |
| 2023 | -17.84% 1762/2656 |
2.19% 1417/2280 |
-6.80% 1712/2385 |
-9.02% 1768/2515 |
-5.18% 1281/2655 |
| 2022 | -27.89% 1513/2207 |
-19.06% 1424/1919 |
5.76% 831/2016 |
-17.65% 1629/2113 |
2.29% 987/2208 |
| 2021 | 11.61% 400/1822 |
-6.32% 994/1255 |
24.71% 108/1330 |
-6.54% 952/1466 |
2.22% 657/1822 |
| 2020 | 61.94% 120/1250 |
3.86% 105/1028 |
28.79% 93/1067 |
5.52% 912/1164 |
14.72% 254/1184 |
| 2019 | 40.88% 243/1092 |
32.80% 160/739 |
-9.53% 663/788 |
6.91% 110/850 |
9.68% 210/918 |
| 2018 | -25.64% 360/834 |
- - |
-14.16% 483/631 |
-11.11% 567/660 |
-10.20% 181/682 |
| 2017 | -12.76% 554/714 |
- - |
- - |
- - |
- - |
| 2016 | -26.38% 491/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 天弘创业板ETF联接C VS. 长安沪深300非周期A(740101) |